• Rick Bartels, MBA

New FDA Payer Communication Guidance

By: Rick Bartels, MBA

One of the most effective methods to provide payer organizations with information about a new products prior to FDA approval is to talk to them directly.

I often hear pharma companies express concern about engaging in payer discussions prior to approval, but the reality is the FDA is in favor of pre-approval payer communications. In fact, the FDA recently released guidance on payer communications for the pharma industry.

According to the guidance on payer communications, pharma companies can share unapproved product and use information with payer organizations as long as they clearly state:

1) The product or use is not approved

2) The product's status in the FDA approval process

3) Details of studies used to test the product

Benefits of pre-approval communication for pharma manufacturers:

- Increased business relationship with payer organization

- Gain payers' perspective on utilization management

- Understand payers' perspective on the competitive landscape within the market

Benefits to the payer:

- Increase awareness of new products

- Payer may delay extending competitive product contracts based on knowledge of a new product coming to market

- Enhances payer/manufacturer relations

Schooner consulting, LLC

Managed care and Market Access Experts


0 views0 comments

Recent Posts

See All

What you need to know about Accumulator programs

By: Rick Bartels, MBA One of the questions that I am hearing more frequently is: What is an accumulator program and what are the implications of these programs on the cost of my patient assistance pro

© 2021 by Digital Therapeutics Commercialization Consultants LLC. Proudly created with Wix.com

  • LinkedIn Social Icon
  • Twitter Social Icon